For example, in a randomised phase II trial comparing axitinib, which, apart from VEGFR, also targets PDGFRß, and c-Kit, with physicians’ best choice of therapy in patients with recurrent GBM, axitinib monotherapy was found to increase the 6-month PFS and overall response rate but not OS [39]. The gene discussed is KDR; the disease is glioblastoma.